New clinical trial platforms to help Alzheimer’s

News-medical.net just released an article on the recently launched Global Alzheimer’s Platform (GAP). This program strives to cut time and costs on Alzheimer’s trials. The article cites that Alzheimer’s treatment development costs up to three times the normal cost of drug development. Ellis Rubinstein, president and CEO of the New York Academy of Science said, “We can no longer afford to have Alzheimer’s clinical trials siloed in a few locations around the world without a means to capture the knowledge that comes from these critical human contributions. Through the development of GAP, government and industry can create more effective and streamlined Alzheimer’s clinical trials, and tap new sources of revenue through innovative public-private partnerships.” To read the full article click here.